文献速递肾小球疾病慢性肾脏病

IgA肾病中估算肾小球滤过率斜率与肾脏结局的关联

Estimated Glomerular Filtration Rate Slope and Kidney Outcomes in IgA Nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2026-04-16

本研究基于日本IgA肾病队列研究(J-IGACS)937例经活检确诊的IgA肾病患者,中位随访6年,采用线性混合效应模型估算个体eGFR斜率,并通过联合模型分析其与复合肾脏结局(eGFR下降≥40%或启动肾脏替代治疗)的关联。结果显示,eGFR斜率每下降1个标准差(即每年多下降0.31 mL/min/1.73 m²),复合肾脏结局风险增加(HR 1.82,P<0.001),且该关联独立于当前eGFR水平。结论支持eGFR斜率作为IgA肾病临床试验的替代终点和风险分层工具。

要点

  • eGFR斜率下降越快,IgA肾病患者复合肾脏结局风险越高(HR 1.82,P<0.001)。
  • eGFR斜率的预后信息独立于当前eGFR水平。
  • eGFR斜率可作为IgA肾病临床试验的替代终点和风险分层指标。

核心结论

  • 在IgA肾病患者中,eGFR斜率可提供超越当前eGFR水平的预后信息。
  • 研究支持将eGFR斜率作为IgA肾病临床试验的可靠替代终点和风险分层工具。

研究设计与样本

  • 研究基于日本IgA肾病队列研究(J-IGACS),纳入937例经活检确诊的IgA肾病患者。
  • 采用线性混合效应模型估算个体eGFR斜率,并利用纵向与生存数据的联合模型分析其与复合肾脏结局的关联,调整临床和病理协变量。

主要发现

  • 中位随访6年期间,78例患者(8.3%)达到复合肾脏结局(eGFR下降≥40%或启动肾脏替代治疗)。
  • eGFR斜率每下降1个标准差(即每年多下降0.31 mL/min/1.73 m²),复合肾脏结局风险显著增加(HR 1.82;P<0.001)。
  • 在基线已接受治疗患者的敏感性分析中关联仍显著,但效应量有所减弱;在至少有5次eGFR测量患者的敏感性分析中结果相似。

临床怎么用

  • 临床中可动态监测IgA肾病患者的eGFR斜率,用于评估疾病进展风险和指导治疗决策。
  • eGFR斜率可作为临床试验中评估治疗效果的替代终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: In IgA nephropathy (IgAN), early surrogate markers that reflect disease progression are critical for understanding long-term outcomes. While prior studies have suggested a potential role for eGFR slope, its validity as a surrogate endpoint requires further validation. We here investigated the association between longitudinal changes in eGFR and kidney outcomes in a large Japanese IgAN cohort. METHODS: Patients with biopsy-confirmed IgAN enrolled in the Japan IgA Nephropathy Cohort Study (J-IGACS) were analyzed. Individual eGFR slopes were estimated using a linear mixed-effects model. The association between eGFR slope and a composite kidney outcome, defined as a ≥ 40% decline in eGFR or the initiation of kidney replacement therapy, was assessed using joint modeling of longitudinal and survival data, adjusting for clinical and histopathological covariates, including current eGFR levels. RESULTS: During a median follow-up of 6 years in 937 patients (mean age 39 years; 51% male), 78 patients (8.3%) reached the composite kidney endpoint. Joint modeling analysis demonstrated that a steeper decline in eGFR slope was significantly associated with a higher risk of adverse kidney outcomes (hazard ratio per 1-standard deviation eGFR slope decrease [i.e. 0.31 mL/min/1.73 m²/year steeper decline], 1.82; P < 0.001). The association remained statistically significant in sensitivity analyses restricted to patients who had already received treatment at baseline, although the effect size was modestly attenuated. Similar results were observed in an additional sensitivity analysis restricted to patients with at least five available eGFR measurements. CONCLUSION: Using joint modeling, we demonstrated that eGFR slope provides prognostic information beyond current eGFR levels in patients with IgAN. Our findings support the use of eGFR slope as a reliable surrogate endpoint for clinical trials and risk stratification in IgAN.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Sasaki T, Tsuboi N, Koike K, et al. Estimated Glomerular Filtration Rate Slope and Kidney Outcomes in IgA Nephropathy. Nephrol Dial Transplant. 2026. PMID: 41990459. doi:10.1093/ndt/gfag089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。